Understanding COVID-19 vaccination program among Indonesian public

Widjaja, Gunawan; Zahari, Marina; Hastuti, Puji; Nugraha, Aat Ruchiat; Kusumawaty, Ira

doi:10.53730/ijhs.v5n3.1429

Cited by 7 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the respondents required hospitalization or had serious AEFIs. This is in line with research from Moderna which recorded that most systemic AEFIs were mild-moderate and the complaints disappear by themselves in all cases (Widjaja et al, 2021).…”

Section: Resultssupporting

confidence: 91%

Adverse events following immunization Post Moderna (mRNA-1273) booster vaccination after two primary doses of CoronaVac

Rakhmadhani¹,

Yulida²,

Fauzan³

et al. 2022

ijhs

View full text Add to dashboard Cite

This study aims to investigate the prevalence of Adverse Events Following Immunization infection among health workers in the Hulu Sungai Utara Regency following two doses of CoronaVac. The study takes a descriptive research method. This research data is taken from two hundred fifty-eight individuals who indicated their willingness to participate in the study. 99 health workers (38.37%) had a history of AEFI at the first and second doses, with symptoms of malaise (36.36%), local pain (32.32%), and fever (22.22%) with an onset of 1–5 days (24.81%), and the majority did not require treatment (72.48 %). The study results showed that almost all health care professionals developed AEFI, both local and systemic, following the third immunization dosage. 257 health care workers (99.6 %) reported experiencing local AEFIs, with pain (95.35 %), swelling (37.60 %), and a red rash (37.60 %). Systemic AEFI was diagnosed in 239 health care workers (92.63 %), with the most common systemic reaction being arthralgia, myalgia (70.54 %), fever (62.02 %), and malaise (38.37 %). The response length was between 1 and 5 days (74.03 %), and 195 health workers (75.58 %) took NSAIDs to alleviate the reaction.

show abstract

Section: Resultssupporting

confidence: 91%

Adverse events following immunization Post Moderna (mRNA-1273) booster vaccination after two primary doses of CoronaVac

Rakhmadhani¹,

Yulida²,

Fauzan³

et al. 2022

ijhs

View full text Add to dashboard Cite

show abstract

“…Nearly 200 million Indonesians between the ages of 18 and 60 have received vaccines due to a 15-month vaccine programme launched by the Indonesian government. Following the Minister of Health's choice, the Indonesian government chooses vaccines deemed safe for its citizens (Widjaja et al, 2021).…”

Section: Document Per Affiliationmentioning

confidence: 99%

Quo Vadis Vaccine Research Trends of Coronavirus Disease-19 in Indonesia and Malaysia: A Bibliometric Analysis

Dwijayani,

Soraya,

Alimuddin

et al. 2023

jcgpp

View full text Add to dashboard Cite

The Coronavirus Disease-19 (COVID-19) has become a centre of attention for several countries, including Indonesia and Malaysia. The two countries are trying to maintain the stability and security of each country from the impact that will be caused. The Indonesian and Malaysian governments decided to import vaccines from several countries to reduce the spread of the disease in the global community. However, to deal with the limitations of imported vaccines, Malaysia and Indonesia are conducting various studies related to COVID-19 vaccine research. This study will observe how Indonesia and Malaysia respond to vaccine research trends related to COVID-19 from 2020 to 2022. This study uses a qualitative descriptive method that is produced through bibliometric analysis to analyse data collected from Scopus. In addition, the authors also use several kinds of literature from reputable journals to add references and information related to the research. The results of the bibliometric analysis show that Malaysia has paid more attention to research publications related to COVID-19 than Indonesia. However, Indonesia has received official approval for its first vaccine since September 2021, while Malaysia is in the process of developing its own vaccine. The authors assume this is because Malaysia manages its own local vaccines, while Indonesia does the opposite.

show abstract

“…According to Nugraha et al (2021), vaccination is a step to suppress the number of COVID-19 in the second wave, even though simultaneously, understanding of the importance of vaccines in society is still low (Widjaja et al, 2021). Thus, the government must encourage the acceleration of vaccination and provide an understanding of the importance of vaccines in society.…”

Section: Irawan Bambang Is a Seniormentioning

confidence: 99%

An Exploration Respond of COVID-19 Policy through Social Media in Indonesia

Irawan

Loilatu

Akbar

et al. 2022

pgr

View full text Add to dashboard Cite

This paper explores public responses through social media to the COVID-19 policy in Indonesia; public response to the COVID-19 policy shows that information about COVID-19 is sourced from crowd sources, thus creating misinformation on health information. To answer the research purpose, this research uses NodeXL to explore policy responses through social media Twitter; data collection was carried out from 3-25 July 2021. The result shows the public response to the COVID1-19 policy in Indonesia through topic distribution on social media Twitter. From these findings, 10 topics on social media became public responses to COVID-19 policies. This topic addresses the public's response to the COVID-19 condition in Indonesia and the policies taken by the government. We classify these topics based on the characteristics of public responses that indicate certain conditions such as vaccine policies, medical device crises, hoax information, collaboration, and political conditions. However, this research has limitations on access to the data taken. Therefore, further research can explore the function of social media in post-COVID-19 policies.

show abstract

Understanding COVID-19 vaccination program among Indonesian public

Cited by 7 publications

References 20 publications

Adverse events following immunization Post Moderna (mRNA-1273) booster vaccination after two primary doses of CoronaVac

Adverse events following immunization Post Moderna (mRNA-1273) booster vaccination after two primary doses of CoronaVac

Quo Vadis Vaccine Research Trends of Coronavirus Disease-19 in Indonesia and Malaysia: A Bibliometric Analysis

An Exploration Respond of COVID-19 Policy through Social Media in Indonesia

Contact Info

Product

Resources

About